Browsing by Author "Nakamura, Masaki"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Micropetrosis in hemodialysis patients
    (Elsevier, 2021-11-27) Yajima, Aiji; Tsuchiya, Ken; Burr, David B.; Murata, Taro; Nakamura, Masaki; Inaba, Masaaki; Tominaga, Yoshihiro; Tanizawa, Tatsuhiko; Nakayama, Takashi; Ito, Akemi; Nitta, Kosaku; Anatomy, Cell Biology and Physiology, School of Medicine
    Micropetrosis develops as a result of stagnation of calcium, phosphorus and bone fluid, which appears as highly mineralized bone area in the osteocytic perilacunar/canalicular system regardless of bone turnover of the patients. And microcracks are predisposed to increase in these areas, which leads to increased bone fragility. However, micropetrosis of hemodialysis (HD) patients has not been discussed at all. Micropetrosis area per bone area (Mp.Ar/B·Ar) and osteocyte number per micropetrosis area (Ot.N/Mp.Ar) were measured in nine HD patients with renal hyperparathyroidism (Group I), twelve patients with hypoparathyroidism within 1 year after the treatment of renal hyperparathyroidism (Group II) and seven patients suffering from hypoparathyroidism for over two years (Group III). And bone mineral density (BMD) and tissue mineral density (TMD) were calculated using μCT to evaluate bone mineral content of iliac bone of the patients. These parameters were compared among the three groups. Only Mp.Ar/B·Ar was statistically greater in Group II and III compared to Group I in the parameters of bone mineral content and micropetrosis. However, the other parameters were not statistically different among the three groups. In long-term HD patients, BMD and TMD may be modified by the causes of renal insufficiency and the treatment of renal bone disease. We concluded that Mp.Ar/B·Ar was greater in patients with long-term hypoparathyroidism than both those with short-term hypoparathyroidism and with renal hyperparathyroidism. Special attention should be paid to avoid long-term hypoparathyroidism of the patients from the view point of increased fracture risk caused by increased micropetrosis area.
  • Thumbnail Image
    Item
    Toxicity of Radiosurgery for Brainstem Metastases
    (Elsevier, 2018) Patel, Ajay; Dong, Tuo; Ansari, Shaheryar; Cohen-Gadol, Aaron; Watson, Gordon; de Moraes, Fabio Ynoe; Nakamura, Masaki; Murovic, Judith; Chang, Steven D.; Hatiboglu, Mustafa Aziz; Chung, Caroline; Miller, James; Lautenschlaeger, Tim; Radiation Oncology, School of Medicine
    Background Although stereotactic radiosurgery (SRS) is an effective modality in the treatment of brainstem metastases (BSM), radiation-induced toxicity remains a critical concern. To better understand how severe or life-threatening toxicity is affected by the location of lesions treated in the brainstem, a review of all available studies reporting SRS treatment for BSM was performed. Methods Twenty-nine retrospective studies investigating SRS for BSM were reviewed. Results The rates of grade 3 or greater toxicity, based on the Common Terminology Criteria for Adverse Events, varied from 0 to 9.5% (mean 3.4 ± 2.9%). Overall, the median time to toxicity after SRS was 3 months, with 90% of toxicities occurring before 9 months. A total of 1243 cases had toxicity and location data available. Toxicity rates for lesions located in the medulla were 0.8% (1/131), compared with midbrain and pons, respectively, 2.8% (8/288) and 3.0% (24/811). Conclusions Current data suggest that brainstem substructure location does not predict for toxicity and lesion volume within this cohort with median tumor volumes 0.04–2.8 cc does not predict for toxicity.